Company Overview of Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. It uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines that act through T cell immune responses. The company is developing its lead product candidate, GEN-003, a therapeutic vaccine or an immunotherapy that is in Phase I/IIa trial to treat people with herpes simplex virus-2 (HSV-2) infections. It is also developing GEN-004, a vaccine candidate, which is in Phase I trial to prevent infections caused by pneumococcus; GEN-001 that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinic...
100 Acorn Park Drive
Cambridge, MA 02140
Founded in 2006
Key Executives for Genocea Biosciences, Inc.
Chief Executive Officer
Total Annual Compensation: $334.3K
Chief Medical Officer
Total Annual Compensation: $331.5K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Vice President of Biopharmaceutical Development & Production
Total Annual Compensation: $257.3K
Compensation as of Fiscal Year 2013.
Genocea Biosciences, Inc. Key Developments
Genocea Biosciences, Inc. Presents Data from Phase 1/2a Study of GEN-003
Jul 22 14
Genocea Biosciences, Inc. presented data from a Phase 1/2a study of GEN-003, the company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39(th) Annual International Herpesvirus Workshop, being held July 19, 2014 - July 23, 2014 in Kobe, Japan. Prior HSV-2 immunotherapy candidates investigated by others have failed to meet their clinical endpoints because in each case, these immunotherapies elicited serum neutralizing antibodies against the virus but failed to trigger effective CD4(+) and CD8(+) T cell responses against HSV-2 infected cells. As a result, experts have called for next-generation immunotherapies capable of dispatching T cells to combat HSV-2 infected cells, to limit both viral shedding and symptom recurrences. In this trial, at a dose that reduced viral shedding by up to 52%, more than 90% of subjects demonstrated vaccine-induced T cell responses, defined as greater than 3.5 fold increases from baseline, which remain significantly elevated even 12 months after treatment.
Genocea Biosciences, Inc. Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Jul 21 14
Genocea Biosciences, Inc. announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2). The phase 2 dose optimization study will enroll approximately 300 subjects from 17 institutions in the United States and will study six combinations of two antigen doses (30 micrograms or 60 micrograms) with each of three adjuvant doses (25 micrograms, 50 micrograms, or 75 micrograms) alongside a placebo. All subjects will receive three doses of GEN-003 or placebo at 21-day intervals. The primary end point for the study is the change from baseline in viral shedding rate. The study is also designed to evaluate the impact on percentage of days with genital herpes lesions as reported by patients. Subjects receiving GEN-003 will be followed for 12 months after the last dose.
Genocea Biosciences Mulls Acquisitions
Jul 3 14
Genocea Biosciences, Inc. (NasdaqGM:GNCA), which is planning a follow-on equity offering in the amount of $60 million, is looking for acquisitions. The company stated, “Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary technologies, products or assets.”
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|